Uncomplicated urinary tract infections.

Area of Science:

• Infectious Diseases
• Pharmacology
• Urology

Background:

• Urinary tract infections (UTIs) are highly prevalent in outpatient settings.
• Increasing antibiotic resistance necessitates updated treatment strategies for uncomplicated UTIs.
• The ecological impact of antibiotic use (collateral damage) requires careful consideration.

Purpose of the Study:

• To present updated treatment recommendations for uncomplicated urinary tract infections (UTIs).
• To incorporate antibiotic stewardship principles, including minimizing collateral damage, into UTI management.
• To provide evidence-based guidance for clinicians managing uncomplicated UTIs.

Main Methods:

• Systematic literature review of Medline and Cochrane Library databases for uncomplicated UTI.
• Inclusion of international guidelines in the review process.
• Development of updated recommendations based on synthesized evidence.

Main Results:

• Uncomplicated UTIs are categorized as uncomplicated cystitis (UC) or uncomplicated pyelonephritis (UP).
• First-line treatment for UC now favors fosfomycin-trometamol, nitrofurantoin, or pivmecillinam, moving away from co-trimoxazole/trimethoprim and fluoroquinolones.
• High-dose fluoroquinolones remain a first-line option for uncomplicated pyelonephritis (UP).
• Treatment of asymptomatic bacteriuria is restricted to specific high-risk situations like pregnancy or pre-urological procedures.

Conclusions:

• The updated S3 guideline offers a progressive approach to antibiotic use for uncomplicated UTIs.
• These recommendations aim to enhance the quality of care and promote antimicrobial stewardship.
• The guideline addresses the critical need for effective yet judicious antibiotic selection in common infections.